Human ESC/iPSC-based 'omics' and bioinformatics for translational research

Gerd A. Müller, Kirill V. Tarasov, Rebekah L. Gundry, Kenneth R. Boheler

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

Original languageEnglish (US)
Pages (from-to)e161-e170
JournalDrug Discovery Today: Disease Models
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2012

Fingerprint

Induced Pluripotent Stem Cells
Translational Medical Research
Computational Biology
Cell Line
Regenerative Medicine
Drug Discovery
Proteome
Cell- and Tissue-Based Therapy
Transcriptome
Genome
Technology
Human Embryonic Stem Cells
Cellular Reprogramming

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Human ESC/iPSC-based 'omics' and bioinformatics for translational research. / Müller, Gerd A.; Tarasov, Kirill V.; Gundry, Rebekah L.; Boheler, Kenneth R.

In: Drug Discovery Today: Disease Models, Vol. 9, No. 4, 01.01.2012, p. e161-e170.

Research output: Contribution to journalReview article

Müller, Gerd A. ; Tarasov, Kirill V. ; Gundry, Rebekah L. ; Boheler, Kenneth R. / Human ESC/iPSC-based 'omics' and bioinformatics for translational research. In: Drug Discovery Today: Disease Models. 2012 ; Vol. 9, No. 4. pp. e161-e170.
@article{44347a7546b846928a99de05fb4d18ec,
title = "Human ESC/iPSC-based 'omics' and bioinformatics for translational research",
abstract = "The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.",
author = "M{\"u}ller, {Gerd A.} and Tarasov, {Kirill V.} and Gundry, {Rebekah L.} and Boheler, {Kenneth R.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.ddmod.2012.02.003",
language = "English (US)",
volume = "9",
pages = "e161--e170",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Human ESC/iPSC-based 'omics' and bioinformatics for translational research

AU - Müller, Gerd A.

AU - Tarasov, Kirill V.

AU - Gundry, Rebekah L.

AU - Boheler, Kenneth R.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

AB - The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

UR - http://www.scopus.com/inward/record.url?scp=84876690042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876690042&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2012.02.003

DO - 10.1016/j.ddmod.2012.02.003

M3 - Review article

C2 - 23682293

AN - SCOPUS:84876690042

VL - 9

SP - e161-e170

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 4

ER -